Observational Study:Safety,Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix® (TROMBIXDZ)

Prospective, National, Multicentric, Observational Study to Evaluate the Safety, Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix® (Rivaroxaban).

The rational behind this observational study is to collect real life data about the use of Trombix® (Rivaroxaban) among patients with atrial fibrillation in Algeria . The aim is to evaluate the safety, efficacy and quality of life.

Study Overview

• Status: Completed
• Conditions: Atrial Fibrillation
• Intervention / Treatment: Drug: Trombix® (Rivaroxaban)

Detailed Description

Trombix® (Rivaroxaban) is used for the treatment of patients with atrial fibrillation. BEKER laboratories are conducting an observation study to evaluate its use among Algerian population in regards to its safety, efficacy and the quality of life of patients after its use.

• Study Type: Observational
• Enrollment (Actual): 398

Contacts and Locations

Study Locations

• Algeria
  • Algiers, Algeria
    • Boumaaza Private healthcare
  • Algiers, Algeria
    • CHU Mustapha
  • Annaba, Algeria
    • BEDAI private healthcare
  • Annaba, Algeria
    • Berboucha
  • Batna City, Algeria
    • Boudjelal private healthcare
  • Biskra, Algeria
    • OKBI Private healthcare
  • Blida, Algeria
    • KHAITER Private healthcare
  • Constantine, Algeria
    • AOUICHE private healthcare
  • Constantine, Algeria
    • HAMDI private healthcare
  • M'Sila, Algeria
    • Mouffok private healthcare
  • Oran, Algeria
    • Ali Lahmar private healthcare
  • Oran, Algeria
    • CHU Oran
  • Oran, Algeria
    • EID private healthcare
  • Sidi Bel Abbes, Algeria
    • Sebbagh Private Healthcare
  • Tipasa, Algeria
    • EPH Tipaza
  • Tizi Ouzou, Algeria
    • Fernane private healthcare
  • Tlemcen, Algeria
    • NASSOUR private healthcare

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The subjects in the study were enrolled from different centers (public and private sectors) across different regions in the country; East, Center and West of Algeria.

Description

Inclusion Criteria:

• Patient, male or female, aged ≥ 19 years.
• Patient with a diagnosis of atrial fibrillation who requires treatment with Trombix® or switch of Anti-Vitamin K treatment toTrombix® (patient not balanced with current treatment or wishing to change treatment with better manageability).
• Patient being able to provide free and informed written consent before the study.

Exclusion Criteria:

• Hypersensitivity to the active ingredient or to one of the excipients indicated in the Summary of Product Characteristics of Trombix®
• Clinically significant progressive bleeding.
• Injury or illness, if considered to be at significant risk of major bleeding. This may include: current or recent gastrointestinal ulceration, presence of malignant tumors with a high risk of bleeding, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intra-spinal or intracerebral vascular anomalies.
• Concomitant treatment with any other anticoagulant, for example, unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran exilate, apixaban, etc.) except in specific circumstances of switching from anticoagulant treatment or in the case of administration of UFH at doses necessary to maintain the permeability of a central venous or arterial catheter.
• Liver injury associated with coagulopathy and clinically significant bleeding risk, including cirrhotic patients with Child Pugh score class B or C.
• Pregnancy and breast feeding

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with confirmed diagnosis of Atrial fibrillation; male, female, 19 or more of age with confirmed diagnosis of Atrial fibrillation	Drug: Trombix® (Rivaroxaban); 20mg or 15 mg as per the doctor's prescription; Other Names: Trombix®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of reported Serious Adverse Effects linked to Trombix ®	Assessment of serious adverse effects "major bleeding" linked to Trombix® reported as per the current medical practice for the following:; Incidence of intracranial hemorrhages; Incidence of hemorrhages requiring hospitalization with transfusion; Incidence of fatal hemorrhages; Incidence of critical organ bleeding; Incidence of gastrointestinal bleeding	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Epidemiological profile of patients: demographic data, pathological history, clinical profile at inclusion	Description the epidemiological characteristics of the patients: demographic data, pathological history, clinical profile at inclusion	12 months
Minor hemorrhages linked to Trombix®	Assessment of the Incidence of minor hemorrhages linked to Trombix® leading to definitive cessation of treatment	12 months
Incidence of any adverse effects	Assessment of the incidence rate of any adverse effects	12 months
Incidence of Trombix® treatment interruptions during 12 months of follow-up	Assessment of the percentage of patients who stopped Trombix® treatment during the 12 months of follow-up	12 months
Relative risk linked to each cause for stopping the treatment with Trombix® during follow-up	Identification of the causes behind stopping treatment with Trombix®	12 months
Incidence of severe thromboses: ischemic stroke / MI / non CNS-Systemic embolism	Assessment of the occurrence rate of ischemic stroke and the occurrence rate of systemic embolism during the duration of the study	12 months
Quality of life score	Assessment of the quality of life of patients using a scoring questionnaire adapted to the living conditions of the Algerian population. The scoring varies between the lowest score of 12 and highest of 48. Change in quality of life score during the follow-up period will be evaluated by comparing the mean values.	12 months

Collaborators and Investigators

• Sponsor: Beker Laboratories
• Investigators: Principal Investigator: Pr Aoudia Yazid, EPH Tipaza; Study Chair: Pr ADJEROUD Naima, Faculty of Medicine of Algiers

Study record dates

Study Major Dates

• Study Start (Actual): December 18, 2023
• Primary Completion (Actual): March 30, 2025
• Study Completion (Actual): June 22, 2025

Study Registration Dates

• First Submitted: December 14, 2023
• First Submitted That Met QC Criteria: December 14, 2023
• First Posted (Actual): December 28, 2023

Study Record Updates

• Last Update Posted (Estimated): September 19, 2025
• Last Update Submitted That Met QC Criteria: September 16, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: safety; efficacy; observational; real life
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Arrhythmias, Cardiac; Pathological Conditions, Signs and Symptoms; Atrial Fibrillation; Sulfur Compounds; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Morpholines; Oxazines; Thiophenes; Rivaroxaban
• Other Study ID Numbers: TROMBIX.DZ _version 3

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No